Fragile X Syndrome (FXS) Market Expected to Witness Significant Growth During the Forecast Period (2026-2036) Owing to Advancements in Disease-Modifying Therapies and Expanding Research Pipeline | DelveInsight

The Fragile X Syndrome (FXS) market is expected to witness significant growth across the 7MM during the forecast period (2026-2036), driven by increasing disease awareness, improvements in genetic diagnosis, growing research into disease-modifying therapies, and the anticipated launch of promising pipeline candidates such as BPN14770 (Shionogi), SRX246 (Azevan Pharmaceuticals), MRM-3379 (Mirum Pharmaceuticals), KER-0193 (Kaerus Bioscience), SPG601 (Spinogenix), and others. These emerging therapies are expected to transform the treatment landscape for Fragile X Syndrome by targeting the underlying neurobiological mechanisms rather than providing only symptomatic relief.

DelveInsight's "Fragile X Syndrome Market Insight, Epidemiology, and Market Forecast-2036" report provides a comprehensive analysis of the Fragile X Syndrome market, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, and commercial opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report offers valuable insights into patient burden, competitive intelligence, market access, and future growth opportunities, helping pharmaceutical companies and stakeholders develop effective commercialization strategies.

To know in detail about the Fragile X Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Fragile X Syndrome (FXS) Competitive Landscape

The Fragile X Syndrome (FXS) therapeutic landscape remains highly underserved, with no approved disease-modifying therapies currently available. Existing management focuses on early intervention, behavioral therapy, educational support, speech and occupational therapy, along with off-label pharmacological treatments such as stimulants, selective serotonin reuptake inhibitors (SSRIs), antidepressants, and atypical antipsychotics to manage cognitive, behavioral, and psychiatric symptoms. Growing understanding of synaptic dysfunction and FMR1-related neurobiology has accelerated the development of mechanism-based therapies designed to improve cognition, behavior, language, and daily functioning.

Leading companies advancing the Fragile X Syndrome pipeline include Shionogi (Tetra Therapeutics), Azevan Pharmaceuticals, Mirum Pharmaceuticals, Kaerus Bioscience, Spinogenix, and others developing novel disease-modifying therapies.

BPN14770 (Zatolmilast): Shionogi (Tetra Therapeutics)

BPN14770 (Zatolmilast) is a selective phosphodiesterase-4D (PDE4D) inhibitor being developed for the treatment of Fragile X Syndrome. The therapy is designed to enhance cyclic AMP (cAMP) signaling and improve synaptic plasticity, cognition, and memory deficits associated with FXS. BPN14770 is currently in Phase III clinical development under the EXPERIENCE clinical program, which includes EXPERIENCE-204, EXPERIENCE-301, and EXPERIENCE-302 studies. The therapy received US FDA Orphan Drug Designation (ODD) in 2018. In April 2024, the European Commission granted Orphan Medicinal Product Designation for BPN14770, and in September 2023, the US FDA granted Rare Pediatric Disease Designation. In July 2024, Shionogi announced protocol modifications aimed at improving patient participation by lowering eligibility age, expanding remote visits, adding trial sites, and covering travel support.

SRX246: Azevan Pharmaceuticals
SRX246 is a first-in-class, orally bioavailable, CNS-penetrating vasopressin V1a receptor antagonist being evaluated for Fragile X Syndrome. The therapy has demonstrated the potential to reduce stress, fear, aggression, depression, and anxiety in preclinical studies. SRX246 is currently in Phase II clinical development. According to the report, the company is pursuing Orphan Drug Designation for Fragile X Syndrome. Recently, the US Department of Defense awarded funding to evaluate SRX246 in patients with Fragile X Syndrome, with patient enrollment expected to begin during late Q1/early Q2 2026 across multiple clinical sites.

MRM-3379: Mirum Pharmaceuticals
MRM-3379 is an investigational oral allosteric PDE4D inhibitor licensed by Mirum Pharmaceuticals for the treatment of Fragile X Syndrome. The therapy is intended to improve cognition, language development, and functional outcomes by enhancing intracellular cAMP signaling. The US FDA has granted Fast Track Designation (FTD) to MRM-3379. In December 2025, Mirum Pharmaceuticals announced enrollment of the first participant in the Phase II BLOOM clinical study, while according to the company's 2026 corporate presentation, topline Phase II results are anticipated in 2027.

KER-0193: Kaerus Bioscience
KER-0193 is an investigational therapy being developed by Kaerus Bioscience for Fragile X Syndrome. In May 2025, the therapy received both US FDA Orphan Drug Designation and Rare Pediatric Disease Designation following successful completion of a Phase I clinical study demonstrating a favorable safety profile in healthy volunteers. The therapy continues clinical development as a potential disease-modifying treatment for Fragile X Syndrome.

SPG601: Spinogenix
SPG601 is a first-in-class investigational therapy being developed by Spinogenix for Fragile X Syndrome. In February 2026, Spinogenix announced that a grant from the FRAXA Research Foundation would support principal investigators participating in the ongoing Phase II clinical trial evaluating the safety and efficacy of SPG601 in patients with Fragile X Syndrome.

Discover more about therapies expected to transform the Fragile X Syndrome market @ Fragile X Syndrome Treatment Landscape

Recent Developments in the Fragile X Syndrome Market
• In February 2026, Spinogenix announced FRAXA Research Foundation funding to support investigators participating in the Phase II study evaluating SPG601 in Fragile X Syndrome.
• In December 2025, Mirum Pharmaceuticals enrolled the first participant in the Phase II BLOOM clinical trial evaluating MRM-3379 for Fragile X Syndrome.
• In September 2025, Harmony Biosciences announced topline results from the Phase III RECONNECT study evaluating ZYN002, which did not achieve its primary endpoint because of a higher-than-expected placebo response.
• In May 2025, Kaerus Bioscience received both US FDA Orphan Drug Designation and Rare Pediatric Disease Designation for KER-0193.
• In April 2024, the European Commission granted Orphan Medicinal Product Designation to BPN14770 (Zatolmilast), while the US FDA previously granted Rare Pediatric Disease Designation in September 2023.

What is Fragile X Syndrome (FXS)?

Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and one of the leading known genetic causes of autism spectrum disorder. The disease results from a CGG trinucleotide repeat expansion in the FMR1 gene, causing reduced or absent production of the Fragile X Messenger Ribonucleoprotein (FMRP), which plays an essential role in normal brain development and synaptic function. Individuals with FXS commonly experience intellectual disability, developmental delay, language impairment, anxiety, attention deficits, behavioral abnormalities, and autistic features. Current treatment remains symptom-based, highlighting the significant need for disease-modifying therapies.

Fragile X Syndrome (FXS) Epidemiology Segmentation

The DelveInsight report provides a detailed epidemiological assessment of Fragile X Syndrome across the Seven Major Markets (7MM) during 2022-2036, segmented into:
• Total Diagnosed Prevalent Cases of Fragile X Syndrome
• Gender-specific Prevalent Cases of Fragile X Syndrome
• Age-specific Prevalent Cases of Fragile X Syndrome
• Total Treated Cases of Fragile X Syndrome
• Country-specific epidemiology across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Download the report to explore detailed epidemiology trends, emerging therapies, competitive intelligence, and commercial opportunities in the Fragile X Syndrome market:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Fragile X Syndrome Market Report

• Study Period: 2022-2036
• Coverage: Seven Major Markets (7MM) - United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Key Companies: Shionogi (Tetra Therapeutics), Azevan Pharmaceuticals, Mirum Pharmaceuticals, Kaerus Bioscience, Spinogenix, Harmony Biosciences, and others
• Current Treatment Landscape: Behavioral therapy, speech therapy, occupational therapy, stimulants, SSRIs, antidepressants, antipsychotic agents, and supportive care
• Emerging Therapies: BPN14770 (Zatolmilast), SRX246, MRM-3379, KER-0193, SPG601, and others
• Epidemiology Segmentation: Total diagnosed prevalent cases, gender-specific prevalent cases, age-specific prevalent cases, and total treated cases across the 7MM
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, unmet needs, SWOT analysis, and market forecasts through 2036
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Additional Coverage: Patient journey, Key Opinion Leader (KOL) perspectives, therapy launch assessment, reimbursement dynamics, market access strategies, and analyst views.

To learn more about the Fragile X Syndrome market, epidemiology, and emerging treatment landscape, visit:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Fragile X Syndrome (FXS) Market Report Introduction
• Fragile X Syndrome (FXS) Market Executive Summary
• Key Events
• Fragile X Syndrome (FXS) Market Overview at a Glance
• Fragile X Syndrome (FXS) Disease Background and Overview
• Fragile X Syndrome (FXS) Signs and Symptoms
• Fragile X Syndrome (FXS) Causes
• Fragile X Syndrome (FXS) Diagnosis
• Fragile X Syndrome (FXS) Treatment and Management
• Fragile X Syndrome (FXS) Treatment Guidelines and Recommendations
• Fragile X Syndrome (FXS) Epidemiology and Market Methodology
• Fragile X Syndrome (FXS) Epidemiology Analysis
• Fragile X Syndrome (FXS) Patient Population Analysis
• Fragile X Syndrome (FXS) Current Treatment Landscape
• Fragile X Syndrome (FXS) Emerging Therapies
• Fragile X Syndrome (FXS) Market Size Analysis (2022-2036)
• Fragile X Syndrome (FXS) Market Size by Therapies
• Fragile X Syndrome (FXS) Drug Uptake Analysis
• Fragile X Syndrome (FXS) Pricing Trends and Analogue Assessment
• Fragile X Syndrome (FXS) Conjoint Analysis
• Fragile X Syndrome (FXS) Key Companies
• Fragile X Syndrome (FXS) Key Therapies
• Fragile X Syndrome (FXS) Unmet Needs
• Fragile X Syndrome (FXS) SWOT Analysis
• Fragile X Syndrome (FXS) Key Opinion Leader (KOL) Views
• Fragile X Syndrome (FXS) Market Access and Reimbursement
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.